Evolus (NASDAQ:EOLS – Get Free Report) and Sunny Optical Technology (Group) (OTCMKTS:SNPTF – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.
Analyst Recommendations
This is a breakdown of current recommendations for Evolus and Sunny Optical Technology (Group), as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
| Sunny Optical Technology (Group) | 0 | 0 | 0 | 0 | 0.00 |
Evolus currently has a consensus price target of $16.00, suggesting a potential upside of 138.81%. Given Evolus’ stronger consensus rating and higher probable upside, research analysts clearly believe Evolus is more favorable than Sunny Optical Technology (Group).
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evolus | $297.18 million | 1.48 | -$51.64 million | ($0.67) | -10.00 |
| Sunny Optical Technology (Group) | $5.33 billion | 1.97 | $375.45 million | N/A | N/A |
Sunny Optical Technology (Group) has higher revenue and earnings than Evolus.
Volatility & Risk
Evolus has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Sunny Optical Technology (Group) has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Institutional & Insider Ownership
90.7% of Evolus shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Evolus and Sunny Optical Technology (Group)’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evolus | -14.39% | N/A | -19.03% |
| Sunny Optical Technology (Group) | N/A | N/A | N/A |
Summary
Evolus beats Sunny Optical Technology (Group) on 6 of the 11 factors compared between the two stocks.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
About Sunny Optical Technology (Group)
Sunny Optical Technology (Group) Company Limited, an investment holding company, engages in designing, researching, developing, manufacturing, and selling optical and optical related products, and scientific instruments. The company's Optical Components segment offers glass spherical and aspherical lenses, handset lens sets, vehicle lens sets, security surveillance lens sets, and other lens sets. Its Optoelectronic Products segment comprise handset camera modules, three dimensional optoelectronic products, vehicle modules, and other optoelectronic modules. The company's Optical Instruments segment includes microscopes and intelligent inspection equipment for testing. Its optoelectronic-related products are used in handsets, digital cameras, vehicle imaging and sensing systems, security surveillance systems, virtual reality/augmented reality, and robots, which are combined with optical, electronic, algorithm, and mechanical technologies. In addition, the company engages in the research and development of infrared and semiconductor technologies; trading of optical instruments and optoelectronics products; property leasing activities; and development, service, and consultation of technology; provision of financing services; and import and export agency services. It operates primarily in the People's Republic of China, rest of Asia, Europe, North America, and internationally. The company was founded in 1984 and is headquartered in Yuyao, China.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
